Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
about
Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancerMathematical models of the steps involved in the systemic delivery of a chemotherapeutic to a solid tumor: From circulation to survivalA phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaAngiogenesis and antiangiogenic agents in cervical cancer.New ways to successfully target tumor vasculature in ovarian cancer.AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.Targeting angiopoietin-2 signaling in cancer therapy.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.Peptibodies: An elegant solution for a long-standing problem.Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
P2860
Q26991997-F455233F-80A7-453A-93FF-EEEB851ABFB3Q27023583-9833E4C3-D612-482E-AB67-C4DDEED890A3Q28304566-E028A543-01CD-41FB-AB24-6B79070347CAQ34655335-F067DD8F-62A8-4F9F-BC2C-20954AF1440DQ35928220-51B6F0B1-D88E-4D1A-9133-49DB01BF3756Q36338069-4DD5B052-B3A0-4919-B171-74B0D5650FAFQ36671874-FA498391-DA4E-4C63-BAB5-DC0645850464Q38101997-6CAFBB9A-873E-4568-9077-7EF012726F18Q38178093-34858093-3A50-45F4-9C92-7ED55AA665BAQ38351470-F0B050AC-53D7-4BE1-92BD-C92E6663E5F5Q38757677-51E1F6EB-8AB7-49B4-A5F8-7A0D1F5F5EDDQ39022841-1F52C68C-20C9-4C6D-BC0B-FFB5CB150AC9Q39027815-7ED34D57-E41E-4AB1-A0CD-6A963E520B9AQ41037175-FE8220CC-5001-470B-BE4C-92F1CE40EF38Q46666106-ACBBC4CD-8739-454B-B82C-0A65FCBE4546Q47229048-9EDB1B55-DFDF-4AF8-8E31-D4F99D1D708CQ48369496-214E353D-42DC-4253-8D07-DDBFB90DE5D6
P2860
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Exposure-response relationship ...... mplication for dose selection.
@ast
Exposure-response relationship ...... mplication for dose selection.
@en
type
label
Exposure-response relationship ...... mplication for dose selection.
@ast
Exposure-response relationship ...... mplication for dose selection.
@en
prefLabel
Exposure-response relationship ...... mplication for dose selection.
@ast
Exposure-response relationship ...... mplication for dose selection.
@en
P2093
P2860
P1476
Exposure-response relationship ...... mplication for dose selection.
@en
P2093
Beth Y Karlan
Daniel E Stepan
David M Weinreich
Erik Rasmussen
Ignace B Vergote
Jian-Feng Lu
Lynn Navale
Mita Kuchimanchi
Rebeca Melara
Yu-Nien Sun
P2860
P2888
P304
P356
10.1007/S00280-011-1787-5
P577
2012-01-01T00:00:00Z